temozolomide has been researched along with n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Z; Gu, J; Lin, Y; Liu, W; Liu, X; Lu, B; Lu, W; Mai, J; Mou, Y; Ou-Yang, Y; Sai, K; Sheng, L; Sun, S; Xing, F; Xue, D; Yan, G; Zhang, J; Zhu, W | 1 |
1 other study(ies) available for temozolomide and n4-(2,2-dimethyl-3-oxo-4h-pyrid(1,4)oxazin-6-yl)-5-fluoro-n2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine
| Article | Year |
|---|---|
R406 elicits anti-Warburg effect via Syk-dependent and -independent mechanisms to trigger apoptosis in glioma stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Adhesion; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycolysis; Humans; Mice, Nude; Neoplastic Stem Cells; Oxazines; Oxidative Phosphorylation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Survival Analysis; Syk Kinase; Temozolomide; Xenograft Model Antitumor Assays | 2019 |